Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)

BMC Nephrology

Volumn 18, Issue 1, 2017, Pages

  Robinson, Bruce M ^a,b   Larkina, Maria ^a   Bieber, Brian ^a   Kleophas, Werner ^c   Li, Yun ^a,b   Locatelli, Francesco ^d   McCullough, Keith P ^a   Nolen, Jackie G ^e   Port, Friedrich K ^a   Pisoni, Ronald L ^a  

^a ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Gemeinschaftspraxis und Dialysezentrum Karlstraße   (Germany)

^d A MANZONI HOSPITAL   (Italy)

^e Vifor (International) Inc   (Switzerland)

Author keywords

anemia; ferritin; hemodialysis; hemoglobin; IV iron; TSAT

Indexed keywords

FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TRANSFERRIN;

ADULT; ANEMIA; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; INFORMED CONSENT; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PROSPECTIVE STUDY; TREATMENT OUTCOME; AGED; BLOOD; DISEASE MANAGEMENT; INTERNATIONAL COOPERATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; TRENDS;

ADMINISTRATION, INTRAVENOUS; AGED; ANEMIA; COHORT STUDIES; DISEASE MANAGEMENT; FEMALE; HUMANS; INTERNATIONALITY; IRON; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 85033604293     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/s12882-017-0745-9     Document Type: Article

References (49)

1. Charytan C, Levin N, Al-Saloum M, Hafeez T, Gagnon S, Van Wyck DB. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 2001;37(2):300-7.
2. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR. Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18:975-84.
3. Chang CH, Chang CC, Chiang SS. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin Nephrol. 2002;57(2):136-41.
4. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26(1):41-6.
5. Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19(2):372-9.
6. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int. 2015;87(1):162-8.
7. Boulware EL, Tangri N, Ephraim PL, Scialla JJ, Sozio SM, Crews DC, Shafi T, Miskulin DC, Liu J, St Peter W, Jaar BG, Wu AW, Powe NR, Navaneethan SD, Bandeen-Roche K. Comparative effectiveness studies to improve clinical outcomes in end stage renal disease: the DEcIDE patient outcomes in end stage renal disease study. BMC Nephrol. 2012;6(13):167.
8. Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol. 2013;24(7):1151-8.
9. Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayer WC. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA. 2010;303(9):857-64.
10. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004;15:1623-32.
11. Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, Marcus S, Faich G. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol. 2002;13:734-44.
12. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3070-80.
13. Miskulin DC, Tangri N, Bandeen-Roche K, Zhou J, McDermott A, Meyer KB, Ephraim PL, Michels WM, Jaar BG, Crews DC, Scialla JJ, Sozio SM, Shafi T, Wu AW, Cook C, Boulware LE. Intravenous Iron Exposure and Mortality in Patients on Hemodialysis. Clin J Am Soc Nephrol. 2014;9:1930-9.
14. Tangri N, Miskulin DC, Zhou J, Bandeen-Roche K, Michels WM, Ephraim PL, McDermott A, Crews DC, Scialla JJ, Sozio SM, Shafi T, Jaar BG, Meyer K, Boulware LE. Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study. Nephrol Dial Transplant. 2015;30(4):667-75.
15. Ghoti H, Rachmilewitz EA, Simon-Lopez R, Gaber R, Katzir Z, Konen E, Kushnir T, Girelli D, Campostrini N, Fibach E, Goitein O. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol. 2012;89:87-93.
16. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, Roy M, Machado G, Janklewicz P, Drahi G, Dahan H, Cohen Y. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med. 2012;125(10):991-9.
17. Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002; 22;106(17):2212-7.
18. Fishbane S, Matthew A, Vaziri ND. Iron toxicity: relevance for dialysis patients. Nephrol Dial Transplant. 2014;29(2):255-9.
19. Gupta A, Zhuo J, Zha J, Reddy S, Olp J, Pai A. Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrol. 2010;17;11:16.
20. Kuo KL, Hung SC, Wei YH, Tarng DC. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol. 2008;19(9):1817-26.
21. Zager RA, Johnson AC, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int. 2004;65(6):2108-12.
22. Macdougall IC, Bircher AJ, Eckardt KU, Obrador GT, Pollock CA, Stenvinkel P, Swinkels DW, Wanner C, Weiss G, Chertow GM. Iron management in chronic kidney disease: conclusions from a »Kidney Disease: Improving Global Outcomes» (KDIGO) Controversies Conference. Kidney Int. 2016;89(1):28-39.
23. EU Clinical Trials Register. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002267-25/GB. Accessed 18 May 2015.
24. DeVita MV, Frumkin D, Mittal S, Kamran A, Fishbane S, Michelis MF. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol. 2003;60(5):335-40.
25. Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, Gammaro L, Brocco G, Restivo G, Bernich P, Lupo A, Maschio G. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant. 2001;16:1416-23.
26. Richardson D, Bartlett C, Will EJ. Optimizing Erythropoietin Therapy in Hemodialysis Patients. Am J Kidney Dis. 2001;38(1):109-17.
27. Descomes E, Fellay G. Improved Response to Erythropoietin Therapy with Long-Term Continuous Iron Supplementation. Nephron. 2000;84:196-7.
28. Macdougall IC, Chandler G, Elston O, Harchowal J. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis. 1999;34(4 Suppl 2):S40-6.
29. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000;11(3):530-8.
30. Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis. 1999;34(1):21-8.
31. KDIGO. Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int. 2012;(Suppl 2):279-335.
32. Locatelli F, Barany P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, Hörl W, London G, Vanholder R, Van Biesen W. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice position statement. Nephrol Dial Transplant. 2013;28:1346-59.
33. Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, Szczech L. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis. 2013;62(5):849-59.
34. Moist LM, Troyanov S, White CT, Wazny LD, Wilson JA, McFarlane P, Harwood L, Sood MM, Soroka SD, Bass A, Manns BJ. Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis. 2013;62(5):860-73.
35. National Institute for Health and Care Excellence. Anaemia Management in chronic kidney disease (update). http://www.nice.org.uk/guidance/indevelopment/gid-cgwaver142. Accessed May 2015. To be Published May 2015.
36. McFarlane PA, Pisoni RL, Eichleay MA, Wald R, Port FK, Mendelssohn D. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int. 2010;78(2):215-23.
37. Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, Bommer J, Cruz JM, Kerr PG, Mendelssohn DC, Held PJ, Port FK. Anemia management outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44(1):94-111.
38. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM. Variation in intravenous iron use internationally and over time: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2013;28(10):2570-9.
39. Freburger JK, Ng LJ, Bradbury BD, Kshirsagar AV, Brookhart MA. Changing patterns of anemia management in US hemodialysis patients. Am J Med. 2012;125(9):906-14.
40. DOPPS Practice Monitor. http://www.dopps.org/DPM/. Accessed 6 June 2015.
41. Fuller DS, Pisoni RL, Bieber BA, Port FK, Robinson BM. The DOPPS Practice Monitor for US dialysis care: Update on trends in anemia management 2 years into the bundle. Am J Kidney Dis. 2013;62(6):1213-6.
42. Karaboyas A, Zee J, Morgenstern H, Nolen JG, Hakim R, Kalantar-Zadeh K, Zager P, Pisoni RL, Port FK, Robinson BM. Understanding the Recent Increase in Ferritin Levels in US Dialysis Patients: Potential Impact of Changes in IV Iron ESA Dosing. Clin J Am Soc Nephrol. 2015;10(10):1814-21.
43. Young EW, Goodkin DA, Mapes DL, Port FK, Keen ML, Chen K, Maroni BL, Wolfe RA, Held PJ. The Dialysis Outcomes and Practice Patterns Study: an international hemodialysis study. Kidney Int. 2000;57:S74-81.
44. Pisoni RL, Gillespie BW, Dickinson DM, Chen K, Kutner MH, Wolfe RA. The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology. Am J Kidney Dis. 2004;44(Suppl 2):7-15.
45. IVEware: Imputation and Variance Estimation Software by: Trivellore E. Raghunathan, Peter W. Solenberger, John Van Hoewyk.
46. Eckardt KU, Kim J, Kronenberg F, Aljama P, Anker SD, Canaud B, Molemans B, Stenvinkel P, Schernthaner G, Ireland E, Fouqueray B, Macdougall IC. Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol. 2010;21(10):1765-75.
47. Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, Kitamura K, Fujimoto S, Hase H, Joki N, Fukatsu A, Inoue T, Itakura I, Nakanishi T. Association between hemoglobin variability, serum ferritin levels, and adverse events/ mortality in maintenance hemodialysis patients. Kidney Int. 2014;86:845-54.
48. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int. 2003;64:1514-21.
49. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI. Hemoglobin Variability and Mortality in ESRD. J Am Soc Nephrol. 2007;18(12):3164-70.